March 24, 2021 06:59 AM EDT

After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia

Max Gelman

Senior Editor

About two and a half years after selling off royalties on a disappointing Sanofi-partnered diabetes drug, Zealand Pharma now has its own in-house program to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Af­ter spurn­ing Sanofi for di­a­betes dis­ap­point­ment, Zealand nets FDA ap­proval in se­vere hy­po­glycemia

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Gilead buys experimental HIV vaccines from a small Barcelona biotech